US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.95

-0.1500-0.30%

Volume:279.59K

Turnover:13.96M

Market Cap:15.27B

PE:22.40

High:50.28

Open:50.20

Low:49.55

Close:50.10

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.80

T/O Rate:0.09%

Dividend:2.12

Dividend Rate:4.24%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):20.26

Loading ...

Overview Company News Filings

Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program

MT Newswires Live

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Press Release: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Positive EMA CHMP Opinion For Serplulimab

Simply Wall St.

AbbVie’s EMA Wins For Boey And MAVIRET Expand European Growth Story

Simply Wall St.

Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use

MedinCell: EMA Acceptance and 2026 U.S. Approval Outlook for Olanzapine LAI Underpin Reiterated Buy and €33 Price Target

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results

Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

AmChamSG Recognizes Inaugural Green Planet Champions

S&P 500 Futures Decline In Premarket Trading; Magnum Ice Cream, Figma Lead

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/EMA/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.95,"timestamp":1788379200000,"preClose":50.1,"halted":0,"volume":279593,"delay":0,"changeRate":-0.0029940119760478758,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Pre-Mkt","change":-0.15,"latestTime":"09-03 04:57:11 EDT","open":50.2,"high":50.28,"low":49.55,"amount":13961514.200055001,"amplitude":0.014571,"askPrice":50.22,"askSize":5,"bidPrice":49.01,"bidSize":13,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788442200000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":49.95,"dividendRate":0.042217,"postHourTrading":{"tag":"盘后","latestPrice":49.95,"preClose":49.95,"latestTime":"19:30 EDT","volume":42465,"amount":2122593.290875,"timestamp":1788391808904,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8035232909424552,"impliedVol":0.2782,"impliedVolPercentile":0.8486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.8035232909424552,"shares":305783111,"dividePrice":2.116507,"high":50.28,"amplitude":0.014571,"preClose":50.1,"low":49.55,"week52Low":45.77,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":49.95,"committee":0.444444,"eps":2.229761,"divideRate":0.042373,"volume":279593,"delay":0,"ttmEps":2.229761,"open":50.2,"prevYearClose":49.24,"prevWeekClose":49.9,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.68,"twentyDayClose":51.58,"sixtyDayClose":51.09,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-02","current":22.401504,"percent":0.650794,"low":16.637027,"twenty":17.652754,"median":20.237904,"eighty":21.044205,"high":22.07626,"avg":19.812983,"sd":1.48906,"marketCap":15457441366.45},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-02","current":20.570585,"twenty":17.652754,"median":20.237904,"eighty":21.044205,"marketCap":15457441366.45}],"updateTime":1788425831534},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638653254","title":"Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653254","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653254?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:53","pubTimestamp":1779933233,"startTime":"0","endTime":"0","summary":"Actinogen Medical  reached a common understanding of the pathway to marketing approval for its Alzheimer's disease program in its scheduled scientific advice meeting with the European Medicines Agency , according to a Thursday Australian bourse filing.The understanding includes the specification of regulatory starting materials for the commercial manufacturing of Xanamem  drug substance, design considerations for an additional pivotal clinical trial, as well as the limited number of ancillary clinical pharmacology trials and nonclinical studies required.The understandings also include ensuring the proposed makeup of the planned safety database is consistent with EMA and US Food and Drug Administration  guidelines.The firm said the understandings align closely with the guidance received at an earlier meeting with the US FDA's Neurology-I division.Actinogen Medical's shares rose nearly 3% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7129","EMA.AU","EPV","BK7508","BK4081","EMA","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","EMA.AU","BK1161","BK7129","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638342006","title":"Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638342006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638342006?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:57","pubTimestamp":1779922637,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) just unveiled an announcement. Suzhou Ribo Life Science Co., Ltd. has advanced its cardio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638168897","title":"AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration","url":"https://stock-news.laohu8.com/highlight/detail?id=2638168897","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638168897?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:47","pubTimestamp":1779886020,"startTime":"0","endTime":"0","summary":"Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Inve","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301981/29489/en/AIM-ImmunoTech-Announces-Emerging-Ebola-Opportunity-for-Ampligen-Amid-Escalating-Global-Health-Concerns-and-WHO-Emergency-Declaration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4557","BK4081","EMA","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638021595","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2638021595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638021595?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301817/0/en/BridgeBio-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-BBP-418-for-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4081","BK4585","BBP","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638504968","title":"MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638504968","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638504968?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"EscharEx Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue gu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301772/30505/en/MediWound-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIC","EMA","BK4081","MDWD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549272","title":"Press Release: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549272?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:00","pubTimestamp":1779814800,"startTime":"0","endTime":"0","summary":"--  In May 2026, the Company was informed of a \"negative trend\". opinion on its Marketing Authorization Application from the. Committee for Medicinal Products for Human Use  of the. European Medicines Agency , ahead of the expected CHMP formal. vote in June; the Company plans to request a re-examination. --  EBMT 2026 annual congress: MaaT Pharma presented data from the. pivotal ARES trial of MaaT013  featured in the. --  Revenues of EUR0.8 million in the first quarter of 2026 derived from. \"During the first quarter of 2026, we continued to execute with financial discipline while supporting the advancement of our clinical and regulatory priorities. The drawdown of EIB Tranche B, combined with ongoing operational optimization, has extended our cash runway into November 2026 supporting the upcoming regulatory steps, including the planned re-examination of the Marketing Authorization Application for MaaT013 ,\" stated Eric Soyer, CFO of MaaT Pharma.Europe to Clinigen, allowing MaaT Pharma ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","MET","BK4022","LU1989771016.USD","BK4585","EMA","R","CHMP","03160","BK4604","BK4162","TM","BK4232","BK4588","LU1989772840.SGD","BK4099","LU1291159041.SGD","BK4087","BK4555","BK4081","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515769","title":"Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Positive EMA CHMP Opinion For Serplulimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515769?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:25","pubTimestamp":1779787526,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after winning a positive opinion from the EMA’s CHMP for serplulimab plus chemotherapy in first-line advanced squamous non-small cell lung cancer in Europe.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the positive CHMP opinion and a series of product updates, Shanghai Henlius Biotech’s short term share price return has come under pressure, with the 1 month share price return down 17.22%. However, the 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-posi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-posi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","HK0000320264.USD","HK0000320223.HKD","XBI","CHMP","BK1161","BK4585","DCF","HK0000165453.HKD","BK4581","02696","HK0000306685.HKD","BK4588","HK0000306701.USD","BK4081","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637223372","title":"AbbVie’s EMA Wins For Boey And MAVIRET Expand European Growth Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2637223372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637223372?lang=en_us&edition=fundamental","pubTime":"2026-05-24 11:25","pubTimestamp":1779593131,"startTime":"0","endTime":"0","summary":"AbbVie (NYSE:ABBV) received positive European Medicines Agency opinions for Boey®, its new aesthetics product.\nThe EMA also issued a favorable opinion for MAVIRET®, AbbVie’s oral hepatitis C therapy.\nThese opinions cover up to 30 European countries and precede potential regulatory approvals and launches.\n\nAbbVie enters this regulatory milestone with its stock at $215.7 and a return of 21.5% over the past year. Over the past three years the stock is up 74.6% and over five years it is up...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvies-ema-wins-for-boey-and-maviret-expand-european-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvies-ema-wins-for-boey-and-maviret-expand-european-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1244550577.SGD","LU0320765646.SGD","LU0158827948.USD","SG9999003800.SGD","LU0985320562.USD","EPV","LU0456855351.SGD","IE00BN8TJ469.HKD","IE0000B7K699.USD","BK4559","LU2347655156.SGD","EMA","IE0009355771.USD","LU0965509101.SGD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","ABBV","LU2468319806.SGD","IE000SO60NU8.SGD","LU0708994859.HKD","SG9999001440.SGD","LU0058720904.USD","LU2129689431.USD","BK4588","IE0004445239.USD","LU0310799852.SGD","LU1037948541.HKD","LU2023251221.USD","LU2237443895.HKD","LU1983299246.USD","LU0943347566.SGD","LU0029864427.USD","LU0114720955.EUR","LU0234572021.USD","IE00B19Z3B42.SGD","LU0912757837.SGD","LU1003077747.HKD","LU2237443978.SGD","LU2237443382.USD","LU0965509283.SGD","LU2089283258.USD","LU1934455863.HKD","LU0057025933.USD","LU2237443465.HKD","LU1162221912.USD","SG9999015945.SGD","LU1244550221.USD","LU0823416689.USD","BK4566","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310480","title":"Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310480","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310480?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:10","pubTimestamp":1779459017,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech said its anti-PD-1 monoclonal a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/henlius-wins-key-ema-backing-for-serplulimab-lung-cancer-use?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/henlius-wins-key-ema-backing-for-serplulimab-lung-cancer-use?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4585","EMA","XBI","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392068","title":"MedinCell: EMA Acceptance and 2026 U.S. Approval Outlook for Olanzapine LAI Underpin Reiterated Buy and €33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392068","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637392068?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:55","pubTimestamp":1779440119,"startTime":"0","endTime":"0","summary":"Oscar Haffen Lamm, an analyst from Stifel Nicolaus, reiterated the Buy rating on MedinCell SA. The associated price target is €33.00. Oscar Haffen ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medincell-ema-acceptance-and-2026-u-s-approval-outlook-for-olanzapine-lai-underpin-reiterated-buy-and-e33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medincell-ema-acceptance-and-2026-u-s-approval-outlook-for-olanzapine-lai-underpin-reiterated-buy-and-e33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637235353","title":"Teva announces EMA acceptance of MAA for olanzapine long-acting injectable","url":"https://stock-news.laohu8.com/highlight/detail?id=2637235353","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637235353?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:35","pubTimestamp":1779381337,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for ola...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","EMA","EPV","BK4007","LU1983299246.USD","BK4584","BK4566","BK4081","BK4557","BK4215","BK4588","BK4559","BK4596","MAA","TEVA","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637353639","title":"The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353639","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353639?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:30","pubTimestamp":1779381000,"startTime":"0","endTime":"0","summary":"The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299597/0/en/The-European-Medicines-Agency-Accepts-Teva-s-Marketing-Authorization-Application-for-Olanzapine-Long-Acting-Injectable-TEV-749-for-the-Treatment-of-Schizophrenia-in-Adults.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA","BK4215","BK4588","MDCO","EPV","BK4585","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638701","title":"Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637638701?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361200,"startTime":"0","endTime":"0","summary":"Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq. Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026  -- Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted recent business highlights.\"As a public company we continue our journey to accelerate progress and broaden impact for people living with serious coagulation disorders with strong momentum across our clinical programs,\" said Benny Srensen, Chief Executive Officer of Hemab Therapeutics. \"The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4119","BK4139","BK4588","BK4585","BK4081","BK4539","LENZ","EMA","COAG","GT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636085515","title":"Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2636085515","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636085515?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial. NEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000.The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of the private placements for an aggregate of $200,000 in gross proceeds closed on May 11, 2026; the final May private placement closed on May 18, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LU0053666078.USD","LU1244550577.SGD","BK4007","LU0795875169.SGD","LU2089284900.SGD","LU0267386448.USD","BK4504","BK4081","BK4534","BK4539","BK4588","LU0390134368.USD","LU1064131342.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU1162221912.USD","LU2357305700.SGD","LU0006306889.USD","LU0882574139.USD","BK4232","BK4127","LU0210528500.USD","LU1720051108.HKD","BK4139","LU1791710400.SGD","LU1732800096.USD","LU0528227936.USD","LU2264538146.SGD","LU2089283258.USD","LU0158827781.USD","LU0158827948.USD","LU2111349929.HKD","LU1989772840.SGD","IE00BZ1G4Q59.USD","BK4022","BCLI","EMA","LU1244550221.USD","LU1548497426.USD","LU0971096721.USD","LU1720051017.SGD","R","LU0106261372.USD","LU0795875086.SGD","LU1988902786.USD","LU0234570918.USD","LU0912757837.SGD","LU1244550494.USD","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853691","title":"AmChamSG Recognizes Inaugural Green Planet Champions","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853691","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636853691?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:21","pubTimestamp":1779189660,"startTime":"0","endTime":"0","summary":"2026 AmChamSG Green Planet Energy Forum celebrates leadership and commitment to advancing a more sustainable and resilient energy future.SINGAPORE, May 19, 2026 /PRNewswire/ -- The American Chamber of Commerce in Singapore  recognized the inaugural Green Planet Champions at the 2026 AmChamSG Green Planet Energy Forum on Friday, May 15, 2026, with Guest of Honor Dr. Tan See Leng, Minister for Manpower and Minister-in-charge of Energy and Science & Technology, Ministry of Trade and Industry.During the fireside chat, Minister Tan discussed Singapore's journey in energy transition and how Singapore has managed energy security amid geopolitical developments and global uncertainties.About AmCham Singapore Established in 1973, the American Chamber of Commerce in Singapore  is the largest and the most active international business association in Singapore and Southeast Asia, with over 600 American and other global companies with significant U.S. business interests. AmChamSG is an independent, ","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2983129/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2983129/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/amchamsg-recognizes-inaugural-green-planet-champions-302776090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK7129","BK4081","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089981","title":"S&P 500 Futures Decline In Premarket Trading; Magnum Ice Cream, Figma Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089981?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Magnum Ice Cream Co. N.V.  was up 13.1% in pre-market trading, and Figma Inc. Cl A  was up 10.6%.Broadridge Financial Solutions Inc. , Celanese Corp. , and Emera Inc.  were all posting gains of at least 4%. In early trading, Vicor Corp.  and Enlight Renewable Energy Ltd.  had posted declines, falling 6.2% and 6.2%, respectively.Meanwhile S&P 500 futures were down 0.83%, with futures for the Dow Jones Industrial Average falling 0.47%. The Cboe Volatility Index futures were up 8.62%.In commodities news, Brent crude oil futures were up 2.01%, while gold futures were down 2.48%. Bitcoin was down 1.02% to $80,603.In the previous regular trading session, the S&P 500 and the Dow were up 0.77% and 0.75%, respectively. Stocks in Asia were down overnight, with Japan's NIKKEI 225 Index down 1.99% and China's Shanghai Composite Index falling 1.02%.In af","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","ITOT","SPMO","IJR","BK4109","BK4588","VEU","BK4212","LU0390134368.USD","VBK","ESmain","SPXS","DJX","SPGP","SPYU","SPYV","GSLC","SPYH","RSPN","TSPY","SH","MESmain","BMAY","RSP","GPIX","MOAT","ALLW","DBSC","BK4559","SPYM","BK4581","SPUS",".SPX","SPUU","VTI","IVV","SMAX","SPYD","LU1228905540.USD","MMAX","BK4133","IE0009354923.USD","UPRO","ENLT","BR","SCHX","VV","IVW","SPYG","IJH","SPDN","SPYB","SDS","XYLD","BK4534","FIG","BK4504","SPLV","SPYQ","YSPY","SPXL","CE","LU0545562505.USD","BK4023","SCHB","FIGG","IE0034235188.USD","BK4548","SFY","MICC","VICR","RSPA","JEPI",".DJI","ETFT","BK4226","IVE","BK4585","HIBL","DMAX","SPHQ","OEX","BK4106","BK4096","XDTE","BK4081","RSPU","NOBL","SPYI","LU1228905037.USD","HIBS","SPXU","XLG","SPHD","ACWI","SSO","VTV","OEF","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088937","title":"Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088937","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088937?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:01","pubTimestamp":1778839260,"startTime":"0","endTime":"0","summary":"All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295666/0/en/Positive-Interim-Data-from-Cohorts-1-and-2-of-Tenaya-s-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Demonstrated-Consistent-Reductions-in-Arrhythmia-Burden-for-Adults-with-PKP2-asso.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0566484027.USD","BK4588","ECG","BK4531","BK4007","EMA","BK4081","LU1559883803.SGD","TNYA","BK4585","BK4129","BK4539","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTA","EMA","BK4202","CR","BK4581","ORR","NCI","BK4081","ET","BK4144","BK4561","BK4585","BK4590","BK4161","SCD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635899437","title":"Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899437?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:11","pubTimestamp":1778670660,"startTime":"0","endTime":"0","summary":"CARDAMYST (etripamil) nasal spray launch for PSVT isgaining traction; breadth of unique prescribers supportspotential future adoptionExpress Scripts national formulary coverage secured as company make","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293867/0/en/Milestone-Pharmaceuticals-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4585","LU0566484027.USD","BK4588","ECG","BK4215","MAA","LU1559883803.SGD","AV","BK4129"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}